GlassScriptPhysician profile
Jeffrey S Cerone
NPI 1770782922
$4,323.62
in general payments reported to CMS, 2019-2025
31 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $59.44 · 2021: $113 · 2022: $95.96 · 2023: $452 · 2024: $1,613 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927 · Travel and Lodging: $921 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.20 |
| Travel and Lodging | $920.82 |
| Education | $235.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,549.40 | 2022-2025 | Signia, Ligasure |
| Astellas Pharma US INC | $880.88 | 2019-2025 | Xtandi, Myrbetriq |
| Intuitive Surgical, INC. | $300.83 | 2019-2020 | |
| Convatec INC. | $253.61 | 2023-2025 | |
| Abbvie INC. | $205.87 | 2019-2025 | Lupron Depot |
| Sumitomo Pharma America, INC. | $169.44 | 2023-2025 | Gemtesa, Orgovyx |
| Urogen Pharma, INC. | $163.42 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $107.97 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Tolmar, INC. | $92.58 | 2023-2025 | Eligard, Rubraca |
| Immunitybio, INC. | $64.12 | 2025 | |
| Travere Therapeutics, INC. | $61.96 | 2019-2022 | |
| Cycle Pharmaceuticals INC | $46.18 | 2025 | Venxxiva |
| Tolmar Pharmaceuticals, INC. | $40.32 | 2019 | |
| Ethicon US, LLC | $34.02 | 2019-2025 | Surgiflo Hemostatic Matrix, Ethicon, Surgicel Nu-Knit |
| Ferring Pharmaceuticals INC. | $33.49 | 2019-2025 | Adstiladrin |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $28.26 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $26.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $23.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.51 | 2019 | |
| Teleflex LLC | $23.39 | 2025 | Barrigel |
| Pharmaand Gmbh | $22.72 | 2025 | Rubraca |
| Janssen Biotech, INC. | $21.57 | 2025 | Erleada |
| Laborie Medical Technologies Corp. | $21.46 | 2025 | |
| Telix Pharmaceuticals | $19.22 | 2025 | Illuccix |
| Vertex Pharmaceuticals Incorporated | $19.15 | 2025 | |
| Lilly USA, LLC | $17.90 | 2019 | |
| Boston Scientific Corporation | $16.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.16 | 2019 | |
| Medtronic USA, INC. | $14.20 | 2019 | |
| Karl Storz Endoscopy-America | $13.73 | 2024 | Hopkins |
| Procept Biorobotics Corporation | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cerone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.